Hence, this review aims to describe the main pathogenetic mechanisms by which the immune system fosters the development of NAFLD and its progression to advanced forms including HCC, dealing with the immune therapeutic applications of PD-1/PD-L1 target therapy. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatotic liver disease.